A Phase 3 interventional study of Botulinum Toxin A and Placebo in Glabellar Frown Lines, sponsored by Croma-Pharma GmbH. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Croma-Pharma GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
The study is a parallel-group, randomized, double blind, placebo-controlled study followed by an open label extension.
An interim Analysis will be performed when all subjects finalized the re-evaluation for retreatment visit at week 16 of the first treatment cycle or completed the double blind phase (whichever occurs earlier).
The first treatment cycle of the study will comprise two treatment groups as follows:
After a screening period of up to14 calendar days, subjects will receive the first treatment (BoNT/A-DP or placebo) and attend for visits at 1, 2 and 4 weeks after treatment and at 4 weekly intervals thereafter for evaluation of efficacy and safety (primary and key secondary efficacy endpoints are evaluated in the first treatment cycle in comparison with placebo).
The first treatment cycle will last at least 12 weeks and will end when the subjects qualify for re-treatment (in accordance with the "eligibility for re-treatment criteria"). After the first treatment cycle is completed, all subjects may enter the open label extension phase and will be dosed with BoNT/A-DP (20 U) for subsequent re-treatments.
Evaluation for re-treatment takes place at the earliest at 12 weeks after the first/previous treatment. Subjects who do not qualify for re-treatment at week 12 will have the option (pending eligibility) of re-treatment at a later visit (at 4 weekly intervals thereafter) until they are eligible for re-treatment or until a total of 48 weeks has elapsed since study start. Subjects will attend for visits at 1 and 4 weeks after any re-treatment and at 4 weekly intervals thereafter. At week 2 and week 8 of each open label cycle a telephone call visit will take place. According to the study schedule (Section 2.1 and Section 2.2), a maximum of 4 treatments per subject (4 treatment cycles) is permitted during the study time frame, with treatments separated by a minimum of 12 weeks.
The number of treatments administered per subject will depend on the subject's qualification for re-treatment; however, the last opportunity for re-treatment is at week 48.
Croma-Pharma GmbH is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject had a stable medical condition with no uncontrolled systemic disease.
Exclusion Criteria:
Eligibility Criteria for Retreatment
The following criteria had to be met for retreatment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m injections) into glabellar area.
Drug: Botulinum Toxin A
Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
Drug: Placebo
Open Label Extension Arm where all Subjects from Arm 1 and 2 can receive Experimental Treatment in up to 3 treatment cycles. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.
Drug: Botulinum Toxin A
Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
Also known as: BoNT/A-DP
injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
Also known as: sodium chloride 0,9 %
Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area in up to 3 treatment cycles
Also known as: BoNT/A-DP
Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the Investigators´ and the Subjects´ In-clinic Assessments.
The primary endpoint is the percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 4 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. Thus, the primary endpoint is a composite endpoint comprising investigator and subject assessments of treatment effectiveness. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week 4
Extent of Change in Psychological Impact (Emotional and Social Functioning and Concerns Relating to Glabellar Lines)
Extent of change in psychological impact at week 4 after first treatment, relative to baseline, assessed by * modified Skindex-16 (Glabellar Line Quality of Life Scale, \[GL-QoL\]): Each of 7 items rated on 5-point scale: 0/Never, 1/Rarely, 2/Sometimes, 3/Often, 4/Always bothered, than rescaled to a 0 to 100 standardized score; Emotional Domain is the mean of 4 of the items; Social Functioning Domain is the mean of 3 of the items; Overall score is the mean of all 7 items. All reported scores ranging from 0 (best outcome) to 100 (worst outcome). * validated FACE-Q Appraisal of Lines Between Eyebrows scale: Each of 7 items rated on 4-point scale: 1/Not at all, 2/a little, 3/moderately, 4/extremely. Reported score is the sum of the 7 items, standardized on a scale from 0 (worst outcome) to 100 (best outcome). * Age Appraisal visual analog scale \[VAS\]: Perception of Age compared to actual age, in years ranging from -15 years (best outcome) to +15 years (worst outcome).
Time frame: Week 4
Percentage of Responders at Maximum Frown at Week 12
Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 12 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week 12
Percentage of Responders at Week 16
Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 16 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week 16
Percentage of Responders at Week 20
Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 20 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week 20
The Percentage of Subjects With a ≥ 1 Point Reduction in Facial Wrinkle Scale (FWS) Score at Rest at Week 4 Based Separately on the Investigators´ and the Subjects´ In-clinic Assessments
The Percentage of subjects with a ≥ 1 point reduction in Facial Wrinkle Scale (FWS) score at rest at week 4 in the first treatment cycle, based separately on the investigators' and the subjects' in-clinic assessments (applicable only for subjects who have a FWS score at rest ≥ 1 at baseline). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week 4
Responder Rate at Weeks 1, 2 and 8
The Percentage of responders among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score at maximum frown of 0 or 1 and an improvement ≥ 2 points in FWS score (at maximum frown) during the first treatment cycle visit relative to baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint, at weeks 1, 2 and 8). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week 1, Week 2 and Week 8
The Percentage of Subjects With ≥ 2-point and ≥ 1 Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown)
The percentage of subjects with ≥ 2-point and ≥ 1 reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP and placebo groups during the first treatment cycle visit relative to baseline, based on the independent rater's assessment of photographs (at baseline and visits 2, 4, 12, 16 and 20 weeks after treatment, within the first treatment cycle). The median value of all assessments of the same photography was considered for analysis. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week 2, 4, 12, 16 and 20
Time to Onset of Effect in the BoNT/A-DP and Placebo Groups in the First Treatment Cycle
Time to onset of effect in the BoNT/A-DP and placebo groups in the first treatment cycle, as measured at weeks 1, 2 and 4 based separately on subject and investigator assessment. Onset of effect defined as at least a 1 point improvement in Facial Wrinkle Scale (FWS) score from baseline (at maximum frown). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: From treatment at Day 0 to Week 4 in Treatment Cycle 1
Satisfaction With Treatment, During Each Treatment Cycle, as Assessed by the Validated FACE-Q Satisfaction With Outcome Scale.
The extent of subject perceptions of effect of, and satisfaction with, treatment in the BoNT/A-DP and placebo groups, during each treatment cycle, as assessed by the validated FACE-Q Satisfaction with Outcome Scale. The FACE-Q Satisfaction with Outcome scale is a patient-reported outcome measure designed to assess a patient's satisfaction with the results of a facial aesthetic procedure. This scale comprises six items, each with four response options: "definitely agree," "somewhat agree," "somewhat disagree," and "definitely disagree."
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
The Percentage of Subjects With a ≥ 1 Point Reduction in Facial Wrinkle Scale (FWS) Score at Rest Based on the Independent Rater's Assessment of Photos.
The percentage of subjects with a ≥ 1 point reduction in Facial Wrinkle Scale (FWS) score at rest in the BoNT/A-DP and placebo groups, relative to baseline, during the first treatment cycle, based on the independent rater's assessment of photos. The median value of all assessments of the same photography was considered for analysis. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week 2, Week 4, Week 12, Week 16, Week 20 of Treatment Cycle 1
Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at 4 Weeks After Re-treatment Relative to the Rating at the Preceding End-of-Cycle Visit.
The percentage of subjects with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at 4 weeks after re-treatment relative to the rating at the preceding end-of-cycle visit, based on both the investigator's and the subject's in-clinic assessments (composite endpoint). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
The Percentage of Subjects With ≥ 1-point Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) During the First Treatment Cycle at Week 1, 2, 4, 8, 12, 16 and 20 Relative to Baseline
The percentage of subjects with ≥ 1-point reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP and placebo groups during the first treatment cycle at week 1, 2, 4, 8, 12, 16 and 20 relative to baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint). For week 16 and 20 subjects who were re-treated before the respective visits were counted as non-responders. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 of Treatment Cycle 1
The Percentage of Subjects With ≥ 1-point Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) During Each Re-treatment Cycle at Week 4 Relative to Re-treatment-baseline.
The percentage of subjects with ≥ 1-point reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP during each re-treatment cycle at week 4 relative to re-treatment baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and AEs of Special Interest (AESIs)
Number of Participants with treatment-emergent adverse events (TEAEs), serious AEs (SAEs) and AEs of special interest (AESIs)
Time frame: Through study completion (60 weeks)
Number of Participants With Neutralizing Anti-Drug Antibodies
Number of Participants with Neutralizing Anti-Drug Antibodies Antibody formation, evaluation pre-dose before each treatment, at 4 weeks after each treatment and at the final study visit.
Time frame: Through study completion (60 weeks)
Change From Baseline of Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets
Safety assessments by evaluating change from baseline of Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets as per the study schedule
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Change From Baseline of Alanine Aminotransferase, Alkaline Phosphatase , Aspartate Aminotransferase, Gamma Glutamyl Transpeptidase
Safety assessments by evaluating change from baseline of Alanine Aminotransferase, Alkaline Phosphatase , Aspartate Aminotransferase, Gamma Glutamyl Transpeptidase as per the study schedule
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Change From Baseline of Cholesterol, Glucose, Potassium, Sodium, Urea Nitrogen
Safety assessments by evaluating change from baseline of Cholesterol, Glucose, Potassium, Sodium, Urea Nitrogen as per the study schedule
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Change From to Baseline of Bilirubin, Creatinin
Safety assessments by evaluating change from baseline of Bilirubin, Creatinin as per the study schedule
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Change From Baseline of Erythrocytes
Safety assessments by evaluating change from baseline of Erythrocytes as per the study schedule
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Change From Baseline of Erythrocytes MCV
Safety assessments by evaluating change from baseline of Erythrocytes MCV as per the study schedule
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Change From Baseline of Erythrocyte MCHC, Hemoglobin
Safety assessments by evaluating change from baseline of Erythrocyte MCHC, Hemoglobin as per the study schedule
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Change From Baseline of Lymphocytes/Leukocytes, Monocytes/Leukocytes, Neutrophils/Leukocytes, Basophiles/Leukocytes, Eosinophils/Leukocytes
Safety assessments by evaluating change from baseline of Lymphocytes/leukocytes, Monocytes/leukocytes, Neutrophils/leukocytes, Basophiles/leukocytes, Eosinophils/leukocytes as per the study schedule
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Change From Baseline of Systolic and Diastolic Blood Pressure
Safety assessments by evaluating change from baseline of Systolic and Diastolic Blood Pressure as per the study schedule
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Change From Baseline of Pulse Rate
Safety assessments by evaluating change from baseline of Pulse rate as per the study schedule
Time frame: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)
Number of Participants With Normal and Abnormal Electrocardiogram
Safety assessments by evaluating Electrocardiogram as per the study schedule
Time frame: Week 4 and last visit of Treatment Cycle 1 (End of Cycle procedures), conducted upon confirmation of eligibility for retreatment, assessed starting 12 weeks post-treatment with 4-weekly evaluations up to a max. of 48 weeks post treatment.
| Milestone | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Started | 266 | 89 | 0 |
| Completed | 250 | 84 | 0 |
| Not completed | 16 | 5 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 2 | 0 |
| Withdrew: Covid-19 | 1 | 0 | 0 |
| Withdrew: Early termination due to botox injection while participating in the study | 1 | 0 | 0 |
| Milestone | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Started | 0 | 0 | 323 |
| Completed | 0 | 0 | 297 |
| Not completed | 0 | 0 | 26 |
| Withdrew: Lost to follow-up | 0 | 0 | 13 |
| Withdrew: Physician decision | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 11 |
The primary endpoint is the percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 4 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. Thus, the primary endpoint is a composite endpoint comprising investigator and subject assessments of treatment effectiveness. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A | Placebo |
|---|---|---|
| Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the Investigators´ and the Subjects´ In-clinic Assessments. | 172 | 0 |
Extent of change in psychological impact at week 4 after first treatment, relative to baseline, assessed by * modified Skindex-16 (Glabellar Line Quality of Life Scale, \[GL-QoL\]): Each of 7 items rated on 5-point scale: 0/Never, 1/Rarely, 2/Sometimes, 3/Often, 4/Always bothered, than rescaled to a 0 to 100 standardized score; Emotional Domain is the mean of 4 of the items; Social Functioning Domain is the mean of 3 of the items; Overall score is the mean of all 7 items. All reported scores ranging from 0 (best outcome) to 100 (worst outcome). * validated FACE-Q Appraisal of Lines Between Eyebrows scale: Each of 7 items rated on 4-point scale: 1/Not at all, 2/a little, 3/moderately, 4/extremely. Reported score is the sum of the 7 items, standardized on a scale from 0 (worst outcome) to 100 (best outcome). * Age Appraisal visual analog scale \[VAS\]: Perception of Age compared to actual age, in years ranging from -15 years (best outcome) to +15 years (worst outcome).
| score on a scale | Botulinum Toxin A | Placebo |
|---|---|---|
| Modified Skindex-16 (GL-QoL) Emotional domain - Change from Baseline at Week 4 | -42.27 ± 34.484 | 0.50 ± 20.427 |
| Modified Skindex-16 (GL-QoL) Social Functioning domain - Change from Baseline at Week 4 | -33.14 ± 33.193 | -2.23 ± 31.088 |
| Modified Skindex-16 (GL-QoL) Overall score - Change from Baseline at Week 4 | -38.35 ± 31.075 | -0.67 ± 22.369 |
| FACE-Q Appraisal of Lines Between Eyebrows - Change from Baseline at Week 4 | 46.4 ± 28.62 | -2.9 ± 21.60 |
| Age Appraisal VAS - Change from Baseline at Week 4 | -2.3 ± 4.20 | -0.2 ± 3.42 |
Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 12 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A | Placebo |
|---|---|---|
| Percentage of Responders at Maximum Frown at Week 12 | 56 | 1 |
Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 16 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A | Placebo |
|---|---|---|
| Percentage of Responders at Week 16 | 27 | 1 |
Percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 20 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A | Placebo |
|---|---|---|
| Percentage of Responders at Week 20 | 5 | 0 |
The Percentage of subjects with a ≥ 1 point reduction in Facial Wrinkle Scale (FWS) score at rest at week 4 in the first treatment cycle, based separately on the investigators' and the subjects' in-clinic assessments (applicable only for subjects who have a FWS score at rest ≥ 1 at baseline). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A | Placebo |
|---|---|---|
| Investigator's In-clinic Assessment | 163 | 8 |
| Subject's In-clinic Assessment | 214 | 11 |
The Percentage of responders among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score at maximum frown of 0 or 1 and an improvement ≥ 2 points in FWS score (at maximum frown) during the first treatment cycle visit relative to baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint, at weeks 1, 2 and 8). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A | Placebo |
|---|---|---|
| Week 1 | 150 | 0 |
| Week 2 | 189 | 0 |
| Week 8 | 129 | 0 |
The percentage of subjects with ≥ 2-point and ≥ 1 reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP and placebo groups during the first treatment cycle visit relative to baseline, based on the independent rater's assessment of photographs (at baseline and visits 2, 4, 12, 16 and 20 weeks after treatment, within the first treatment cycle). The median value of all assessments of the same photography was considered for analysis. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A | Placebo |
|---|---|---|
| ≥ 2-point reduction - Week 2 | 150 | 0 |
| ≥ 2-point reduction - Week 4 | 144 | 0 |
| ≥ 2-point reduction - Week 12 | 11 | 1 |
| ≥ 2-point reduction - Week 16 | 4 | 0 |
| ≥ 2-point reduction - Week 20 | 2 | 0 |
| ≥ 1-point reduction - Week 2 | 235 | 6 |
| ≥ 1-point reduction - Week 4 | 234 | 9 |
| ≥ 1-point reduction - Week 12 | 71 | 5 |
| ≥ 1-point reduction - Week 16 | 29 | 0 |
| ≥ 1-point reduction - Week 20 | 21 | 1 |
Time to onset of effect in the BoNT/A-DP and placebo groups in the first treatment cycle, as measured at weeks 1, 2 and 4 based separately on subject and investigator assessment. Onset of effect defined as at least a 1 point improvement in Facial Wrinkle Scale (FWS) score from baseline (at maximum frown). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Days | Botulinum Toxin A | Placebo |
|---|---|---|
| Time to Onset of Effect in the BoNT/A-DP and Placebo Groups in the First Treatment Cycle | 8 (8 to 9) | NA (NA to NA) |
The extent of subject perceptions of effect of, and satisfaction with, treatment in the BoNT/A-DP and placebo groups, during each treatment cycle, as assessed by the validated FACE-Q Satisfaction with Outcome Scale. The FACE-Q Satisfaction with Outcome scale is a patient-reported outcome measure designed to assess a patient's satisfaction with the results of a facial aesthetic procedure. This scale comprises six items, each with four response options: "definitely agree," "somewhat agree," "somewhat disagree," and "definitely disagree."
| Participants | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Cycle 1 Week 4 - pleased — Definitely disagree | 16 | 78 | — |
| Cycle 1 Week 4 - pleased — Somewhat disagree | 13 | 3 | — |
| Cycle 1 Week 4 - pleased — Somewhat agree | 46 | 4 | — |
| Cycle 1 Week 4 - pleased — Definitely agree | 189 | 1 | — |
| Cycle 1 Week 4 - pleased — Missing | 2 | 3 | — |
| Cycle 1 Week 4 - expected — Definitely disagree | 17 | 74 | — |
| Cycle 1 Week 4 - expected — Somewhat disagree | 27 | 7 | — |
| Cycle 1 Week 4 - expected — Somewhat agree | 69 | 5 | — |
| Cycle 1 Week 4 - expected — Definitely agree | 151 | 0 | — |
| Cycle 1 Week 4 - expected — Missing | 2 | 3 | — |
| Cycle 1 Week 4 - great — Definitely disagree | 23 | 77 | — |
| Cycle 1 Week 4 - great — Somewhat disagree | 20 | 7 | — |
| Cycle 1 Week 4 - great — Somewhat agree | 58 | 2 | — |
| Cycle 1 Week 4 - great — Definitely agree | 163 | 0 | — |
| Cycle 1 Week 4 - great — Missing | 2 | 3 | — |
| Cycle 1 Week 4 - look in the mirror — Definitely disagree | 18 | 74 | — |
| Cycle 1 Week 4 - look in the mirror — Somewhat disagree | 34 | 10 | — |
| Cycle 1 Week 4 - look in the mirror — Somewhat agree | 101 | 2 | — |
| Cycle 1 Week 4 - look in the mirror — Definitely agree | 111 | 0 | — |
| Cycle 1 Week 4 - look in the mirror — Missing | 2 | 3 | — |
| Cycle 1 Week 4 - fantastic — Definitely disagree | 25 | 78 | — |
| Cycle 1 Week 4 - fantastic — Somewhat disagree | 31 | 7 | — |
| Cycle 1 Week 4 - fantastic — Somewhat agree | 74 | 1 | — |
| Cycle 1 Week 4 - fantastic — Definitely agree | 134 | 0 | — |
| Cycle 1 Week 4 - fantastic — Missing | 2 | 3 | — |
| Cycle 1 Week 4 - miraculous — Definitely disagree | 31 | 78 | — |
| Cycle 1 Week 4 - miraculous — Somewhat disagree | 46 | 8 | — |
| Cycle 1 Week 4 - miraculous — Somewhat agree | 88 | 0 | — |
| Cycle 1 Week 4 - miraculous — Definitely agree | 99 | 0 | — |
| Cycle 1 Week 4 - miraculous — Missing | 2 | 3 | — |
| Cycle 2 Week 4 - pleased — Definitely disagree | — | — | 17 |
| Cycle 2 Week 4 - pleased — Somewhat disagree | — | — | 20 |
| Cycle 2 Week 4 - pleased — Somewhat agree | — | — | 75 |
| Cycle 2 Week 4 - pleased — Definitely agree | — | — | 200 |
| Cycle 2 Week 4 - pleased — Missing | — | — | 11 |
| Cycle 2 Week 4 - expected — Definitely disagree | — | — | 24 |
| Cycle 2 Week 4 - expected — Somewhat disagree | — | — | 34 |
| Cycle 2 Week 4 - expected — Somewhat agree | — | — | 78 |
| Cycle 2 Week 4 - expected — Definitely agree | — | — | 176 |
| Cycle 2 Week 4 - expected — Missing | — | — | 11 |
| Cycle 2 Week 4 - great — Definitely disagree | — | — | 30 |
| Cycle 2 Week 4 - great — Somewhat disagree | — | — | 23 |
| Cycle 2 Week 4 - great — Somewhat agree | — | — | 80 |
| Cycle 2 Week 4 - great — Definitely agree | — | — | 179 |
| Cycle 2 Week 4 - great — Missing | — | — | 11 |
| Cycle 2 Week 4 - look in the mirror — Definitely disagree | — | — | 25 |
| Cycle 2 Week 4 - look in the mirror — Somewhat disagree | — | — | 47 |
| Cycle 2 Week 4 - look in the mirror — Somewhat agree | — | — | 111 |
| Cycle 2 Week 4 - look in the mirror — Definitely agree | — | — | 129 |
| Cycle 2 Week 4 - look in the mirror — Missing | — | — | 11 |
| Cycle 2 Week 4 - fantastic — Definitely disagree | — | — | 36 |
| Cycle 2 Week 4 - fantastic — Somewhat disagree | — | — | 46 |
| Cycle 2 Week 4 - fantastic — Somewhat agree | — | — | 90 |
| Cycle 2 Week 4 - fantastic — Definitely agree | — | — | 140 |
| Cycle 2 Week 4 - fantastic — Missing | — | — | 11 |
| Cycle 2 Week 4 - miraculous — Definitely disagree | — | — | 52 |
| Cycle 2 Week 4 - miraculous — Somewhat disagree | — | — | 53 |
| Cycle 2 Week 4 - miraculous — Somewhat agree | — | — | 105 |
| Cycle 2 Week 4 - miraculous — Definitely agree | — | — | 102 |
| Cycle 2 Week 4 - miraculous — Missing | — | — | 11 |
| Cycle 3 Week 4 - pleased — Definitely disagree | — | — | 16 |
| Cycle 3 Week 4 - pleased — Somewhat disagree | — | — | 19 |
| Cycle 3 Week 4 - pleased — Somewhat agree | — | — | 60 |
| Cycle 3 Week 4 - pleased — Definitely agree | — | — | 166 |
| Cycle 3 Week 4 - pleased — Missing | — | — | 4 |
| Cycle 3 Week 4 - expected — Definitely disagree | — | — | 20 |
| Cycle 3 Week 4 - expected — Somewhat disagree | — | — | 23 |
| Cycle 3 Week 4 - expected — Somewhat agree | — | — | 62 |
| Cycle 3 Week 4 - expected — Definitely agree | — | — | 156 |
| Cycle 3 Week 4 - expected — Missing | — | — | 4 |
| Cycle 3 Week 4 - great — Definitely disagree | — | — | 24 |
| Cycle 3 Week 4 - great — Somewhat disagree | — | — | 30 |
| Cycle 3 Week 4 - great — Somewhat agree | — | — | 56 |
| Cycle 3 Week 4 - great — Definitely agree | — | — | 151 |
| Cycle 3 Week 4 - great — Missing | — | — | 4 |
| Cycle 3 Week 4 - look in the mirror — Definitely disagree | — | — | 26 |
| Cycle 3 Week 4 - look in the mirror — Somewhat disagree | — | — | 31 |
| Cycle 3 Week 4 - look in the mirror — Somewhat agree | — | — | 100 |
| Cycle 3 Week 4 - look in the mirror — Definitely agree | — | — | 104 |
| Cycle 3 Week 4 - look in the mirror — Missing | — | — | 4 |
| Cycle 3 Week 4 - fantastic — Definitely disagree | — | — | 35 |
| Cycle 3 Week 4 - fantastic — Somewhat disagree | — | — | 31 |
| Cycle 3 Week 4 - fantastic — Somewhat agree | — | — | 72 |
| Cycle 3 Week 4 - fantastic — Definitely agree | — | — | 123 |
| Cycle 3 Week 4 - fantastic — Missing | — | — | 4 |
| Cycle 3 Week 4 - miraculous — Definitely disagree | — | — | 52 |
| Cycle 3 Week 4 - miraculous — Somewhat disagree | — | — | 34 |
| Cycle 3 Week 4 - miraculous — Somewhat agree | — | — | 77 |
| Cycle 3 Week 4 - miraculous — Definitely agree | — | — | 98 |
| Cycle 3 Week 4 - miraculous — Missing | — | — | 4 |
| Cycle 4 Week 4 - pleased — Definitely disagree | — | — | 12 |
| Cycle 4 Week 4 - pleased — Somewhat disagree | — | — | 6 |
| Cycle 4 Week 4 - pleased — Somewhat agree | — | — | 37 |
| Cycle 4 Week 4 - pleased — Definitely agree | — | — | 83 |
| Cycle 4 Week 4 - pleased — Missing | — | — | 1 |
| Cycle 4 Week 4 - expected — Definitely disagree | — | — | 10 |
| Cycle 4 Week 4 - expected — Somewhat disagree | — | — | 17 |
| Cycle 4 Week 4 - expected — Somewhat agree | — | — | 34 |
| Cycle 4 Week 4 - expected — Definitely agree | — | — | 77 |
| Cycle 4 Week 4 - expected — Missing | — | — | 1 |
| Cycle 4 Week 4 - great — Definitely disagree | — | — | 17 |
| Cycle 4 Week 4 - great — Somewhat disagree | — | — | 16 |
| Cycle 4 Week 4 - great — Somewhat agree | — | — | 33 |
| Cycle 4 Week 4 - great — Definitely agree | — | — | 72 |
| Cycle 4 Week 4 - great — Missing | — | — | 1 |
| Cycle 4 Week 4 - look in the mirror — Definitely disagree | — | — | 15 |
| Cycle 4 Week 4 - look in the mirror — Somewhat disagree | — | — | 18 |
| Cycle 4 Week 4 - look in the mirror — Somewhat agree | — | — | 55 |
| Cycle 4 Week 4 - look in the mirror — Definitely agree | — | — | 50 |
| Cycle 4 Week 4 - look in the mirror — Missing | — | — | 1 |
| Cycle 4 Week 4 - fantastic — Definitely disagree | — | — | 21 |
| Cycle 4 Week 4 - fantastic — Somewhat disagree | — | — | 16 |
| Cycle 4 Week 4 - fantastic — Somewhat agree | — | — | 46 |
| Cycle 4 Week 4 - fantastic — Definitely agree | — | — | 55 |
| Cycle 4 Week 4 - fantastic — Missing | — | — | 1 |
| Cycle 4 Week 4 - miraculous — Definitely disagree | — | — | 29 |
| Cycle 4 Week 4 - miraculous — Somewhat disagree | — | — | 23 |
| Cycle 4 Week 4 - miraculous — Somewhat agree | — | — | 45 |
| Cycle 4 Week 4 - miraculous — Definitely agree | — | — | 41 |
| Cycle 4 Week 4 - miraculous — Missing | — | — | 1 |
The percentage of subjects with a ≥ 1 point reduction in Facial Wrinkle Scale (FWS) score at rest in the BoNT/A-DP and placebo groups, relative to baseline, during the first treatment cycle, based on the independent rater's assessment of photos. The median value of all assessments of the same photography was considered for analysis. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A | Placebo |
|---|---|---|
| Week 2 | 106 | 9 |
| Week 4 | 100 | 13 |
| Week 12 | 37 | 8 |
| Week 16 | 21 | 0 |
| Week 20 | 11 | 1 |
The percentage of subjects with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at 4 weeks after re-treatment relative to the rating at the preceding end-of-cycle visit, based on both the investigator's and the subject's in-clinic assessments (composite endpoint). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A Open Label Extension Arm |
|---|---|
| Week 4 after 1st Re-treatment | 153 |
| Week 4 after 2nd Re-treatment | 119 |
| Week 4 after 3rd Re-treatment | 43 |
The percentage of subjects with ≥ 1-point reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP and placebo groups during the first treatment cycle at week 1, 2, 4, 8, 12, 16 and 20 relative to baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint). For week 16 and 20 subjects who were re-treated before the respective visits were counted as non-responders. FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A | Placebo |
|---|---|---|
| Week 1 | 220 | 2 |
| Week 2 | 234 | 0 |
| Week 4 | 236 | 0 |
| Week 8 | 213 | 1 |
| Week 12 | 162 | 2 |
| Week 16 | 94 | 1 |
| Week 20 | 46 | 0 |
The percentage of subjects with ≥ 1-point reduction in Facial Wrinkle Scale (FWS) score (at maximum frown) in the BoNT/A-DP during each re-treatment cycle at week 4 relative to re-treatment baseline, based on both the investigators' and the subjects' in-clinic assessments (composite endpoint). FWS scores are a four-point rating scale as follows: 0 = no facial wrinkles; 1 = mild facial wrinkles; 2 = moderate facial wrinkles; and 3 = severe facial wrinkles.
| Participants | Botulinum Toxin A Open Label Extension Arm |
|---|---|
| Week 4 after 1st Re-treatment | 267 |
| Week 4 after 2nd Re-treatment | 210 |
| Week 4 after 3rd Re-treatment | 104 |
Number of Participants with treatment-emergent adverse events (TEAEs), serious AEs (SAEs) and AEs of special interest (AESIs)
| Participants | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Subjects with any Treatment Emergent Adverse Event (TEAE) | 48 | 14 | 80 |
| Subjects with any Study Medication Related TEAE | 4 | 0 | 8 |
| Subjects with any Injection Procedure Related TEAE | 4 | 0 | 6 |
| Subjects with any Severe TEAE | 1 | 0 | 3 |
| Subjects with severe study drug related TEAE | 0 | 0 | 0 |
| Subjects with severe injection procedure related TEAE | 0 | 0 | 0 |
| Subjects with any Serious TEAE | 1 | 1 | 4 |
| Subjects with any Adverse Events of Special Interest (AESI) | 1 | 0 | 7 |
| Subjects with any TEAE leading to discontinuation | 0 | 0 | 0 |
Number of Participants with Neutralizing Anti-Drug Antibodies Antibody formation, evaluation pre-dose before each treatment, at 4 weeks after each treatment and at the final study visit.
| Participants | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Baseline - Anti-Drug Antibodies (ADA) Screening Assay - Reactive | 23 | 4 | — |
| Baseline - ADA Confirmation Assay - Confirmed | 0 | 0 | — |
| End of Study - ADA Screening Assay - Reactive | 0 | 0 | 21 |
| End of Study - ADA Confirmation Assay - Confirmed | 0 | 0 | 0 |
Safety assessments by evaluating change from baseline of Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets as per the study schedule
| x10^9 cells/L | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Week 4 of cycle 1 - Basophils (x10^9 cells/L) | 0.004 ± 0.0413 | 0.012 ± 0.0556 | — |
| Week 4 of cycle 1 - Eosinophils (x10^9 cells/L) | 0.006 ± 0.0726 | 0.007 ± 0.0767 | — |
| Week 4 of cycle 1 - Leukocytes (x10^9 cells/L) | -0.029 ± 1.4925 | 0.227 ± 1.4308 | — |
| Week 4 of cycle 1 - Lymphocytes (x10^9 cells/L) | -0.038 ± 0.4554 | -0.027 ± 0.4222 | — |
| Week 4 of cycle 1 - Monocytes (x10^9 cells/L) | -0.027 ± 0.1607 | -0.019 ± 0.2154 | — |
| Week 4 of cycle 1 - Neutrophils (x10^9 cells/L) | 0.027 ± 1.3211 | 0.252 ± 1.1477 | — |
| Week 4 of cycle 1 - Platelets (x10^9 cells/L) | 0.3 ± 37.31 | -0.8 ± 38.87 | — |
| Week 4 of cycle 2 - Basophils (x10^9 cells/L) | — | — | -0.002 ± 0.0565 |
| Week 4 of cycle 2 - Eosinophils (x10^9 cells/L) | — | — | 0.009 ± 0.0998 |
| Week 4 of cycle 2 - Leukocytes (x10^9 cells/L) | — | — | 0.000 ± 1.5182 |
| Week 4 of cycle 2 - Lymphocytes (x10^9 cells/L) | — | — | 0.043 ± 0.4282 |
| Week 4 of cycle 2 - Monocytes (x10^9 cells/L) | — | — | -0.002 ± 0.1123 |
| Week 4 of cycle 2 - Neutrophils (x10^9 cells/L) | — | — | -0.048 ± 1.3470 |
| Week 4 of cycle 2 - Platelets (x10^9 cells/L) | — | — | 6.1 ± 37.89 |
| Week 4 of cycle 3 - Basophils (x10^9 cells/L) | — | — | -0.018 ± 0.0496 |
| Week 4 of cycle 3 - Eosinophils (x10^9 cells/L) | — | — | -0.002 ± 0.1059 |
| Week 4 of cycle 3 - Leukocytes (x10^9 cells/L) | — | — | -0.050 ± 2.0753 |
| Week 4 of cycle 3 - Lymphocytes (x10^9 cells/L) | — | — | 0.021 ± 0.4473 |
| Week 4 of cycle 3 - Monocytes (x10^9 cells/L) | — | — | -0.018 ± 0.1246 |
| Week 4 of cycle 3 - Neutrophils (x10^9 cells/L) | — | — | -0.034 ± 1.9383 |
| Week 4 of cycle 3 - Platelets (x10^9 cells/L) | — | — | 6.1 ± 39.16 |
| Week 4 of cycle 4 - Basophils (x10^9 cells/L) | — | — | -0.019 ± 0.0475 |
| Week 4 of cycle 4 - Eosinophils (x10^9 cells/L) | — | — | -0.026 ± 0.0859 |
| Week 4 of cycle 4 - Leukocytes (x10^9 cells/L) | — | — | -0.404 ± 1.5800 |
| Week 4 of cycle 4 - Lymphocytes (x10^9 cells/L) | — | — | 0.003 ± 0.4665 |
| Week 4 of cycle 4 - Monocytes (x10^9 cells/L) | — | — | -0.025 ± 0.1698 |
| Week 4 of cycle 4 - Neutrophils (x10^9 cells/L) | — | — | -0.344 ± 1.3644 |
| Week 4 of cycle 4 - Platelets (x10^9 cells/L) | — | — | 0.4 ± 41.64 |
Safety assessments by evaluating change from baseline of Alanine Aminotransferase, Alkaline Phosphatase , Aspartate Aminotransferase, Gamma Glutamyl Transpeptidase as per the study schedule
| U/L | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Week 4 of cycle 1 - Alanine Aminotransferase (U/L) | -0.1 ± 9.32 | 1.9 ± 19.35 | — |
| Week 4 of cycle 1 - Alkaline phosphatase (U/L) | -0.8 ± 10.99 | -0.5 ± 12.30 | — |
| Week 4 of cycle 1 - Aspartate Aminotransferase (U/L) | 0.2 ± 11.28 | 0.1 ± 8.63 | — |
| Week 4 of cycle 1 - Gamma Glutamyl Transpeptidase (U/L) | 0.8 ± 50.89 | 0.8 ± 12.41 | — |
| Week 4 of cycle 2 - Alanine Aminotransferase (U/L) | — | — | 1.1 ± 10.68 |
| Week 4 of cycle 2 - Alkaline phosphatase (U/L) | — | — | 0.9 ± 9.42 |
| Week 4 of cycle 2 - Aspartate Aminotransferase (U/L) | — | — | -0.2 ± 12.76 |
| Week 4 of cycle 2 - Gamma Glutamyl Transpeptidase (U/L) | — | — | 1.3 ± 11.09 |
| Week 4 of cycle 3 - Alanine Aminotransferase (U/L) | — | — | -0.4 ± 13.43 |
| Week 4 of cycle 3 - Alkaline phosphatase (U/L) | — | — | 0.6 ± 10.89 |
| Week 4 of cycle 3 - Aspartate Aminotransferase (U/L) | — | — | -1.0 ± 14.73 |
| Week 4 of cycle 3 - Gamma Glutamyl Transpeptidase (U/L) | — | — | 0.0 ± 9.64 |
| Week 4 of cycle 4 - Alanine Aminotransferase (U/L) | — | — | -0.2 ± 10.82 |
| Week 4 of cycle 4 - Alkaline phosphatase (U/L) | — | — | 0.9 ± 10.75 |
| Week 4 of cycle 4 - Aspartate Aminotransferase (U/L) | — | — | -1.6 ± 14.54 |
| Week 4 of cycle 4 - Gamma Glutamyl Transpeptidase (U/L) | — | — | 1.0 ± 9.59 |
Safety assessments by evaluating change from baseline of Cholesterol, Glucose, Potassium, Sodium, Urea Nitrogen as per the study schedule
| mmol/L | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Week 4 of cycle 1 - Cholesterol (mmol/L) | -0.119 ± 0.6477 | -0.049 ± 0.5400 | — |
| Week 4 of of cycle 1 - Glucose (mmol/L) | 0.317 ± 1.1751 | 0.290 ± 0.9429 | — |
| Week 4 of of cycle 1 - Potassium (mmol/L) | -0.06 ± 0.405 | -0.09 ± 0.431 | — |
| Week 4 of of cycle 1 - Sodium (mmol/L) | -0.1 ± 2.39 | -0.3 ± 2.35 | — |
| Week 4 of of cycle 1 - Urea nitrogen (mmol/L) | 0.01 ± 1.356 | 0.00 ± 1.123 | — |
| Week 4 of cycle 2 - Cholesterol (mmol/L) | — | — | 0.07 ± 0.5910 |
| Week 4 of of cycle 2 - Glucose (mmol/L) | — | — | 0.086 ± 1.2927 |
| Week 4 of of cycle 2 - Potassium (mmol/L) | — | — | 0.03 ± 0.391 |
| Week 4 of of cycle 2 - Sodium (mmol/L) | — | — | -0.1 ± 2.28 |
| Week 4 of of cycle 2 - Urea nitrogen (mmol/L) | — | — | -0.05 ± 1.277 |
| Week 4 of cycle 3 - Cholesterol (mmol/L) | — | — | 0.021 ± 0.7421 |
| Week 4 of of cycle 3 - Glucose (mmol/L) | — | — | 0.185 ± 1.5644 |
| Week 4 of of cycle 3 - Potassium (mmol/L) | — | — | 0.03 ± 0.415 |
| Week 4 of of cycle 3 - Sodium (mmol/L) | — | — | 0.1 ± 2.44 |
| Week 4 of of cycle 3 - Urea nitrogen (mmol/L) | — | — | 0.01 ± 1.272 |
| Week 4 of of cycle 4 - Cholesterol (mmol/L) | — | — | 0.040 ± 0.6614 |
| Week 4 of of cycle 4 - Glucose (mmol/L) | — | — | -0.098 ± 1.9131 |
| Week 4 of of cycle 4 - Potassium (mmol/L) | — | — | 0.08 ± 0.039 |
| Week 4 of of cycle 4 - Sodium (mmol/L) | — | — | 0.2 ± 1.87 |
| Week 4 of of cycle 4 - Urea nitrogen (mmol/L) | — | — | 0.06 ± 1.398 |
Safety assessments by evaluating change from baseline of Bilirubin, Creatinin as per the study schedule
| μmol/L | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Week 4 of cycle 1 - Bilirubin (μmol/L) | 0.05 ± 3.555 | -0.14 ± 3.597 | — |
| Week 4 of cycle 1 - Creatinine (μmol/L) | 0.52 ± 8.404 | -0.30 ± 6.556 | — |
| Week 4 of cycle 2 - Bilirubin (μmol/L) | — | — | -0.12 ± 3.329 |
| Week 4 of cycle 2 - Creatinine (μmol/L) | — | — | -0.49 ± 8.550 |
| Week 4 of cycle 3 - Bilirubin (μmol/L) | — | — | -0.14 ± 3.283 |
| Week 4 of cycle 3 - Creatinine (μmol/L) | — | — | 0.06 ± 9.553 |
| Week 4 of cycle 4 - Bilirubin (μmol/L) | — | — | 0.52 ± 3.203 |
| Week 4 of cycle 4 - Creatinine (μmol/L) | — | — | -0.66 ± 9.536 |
Safety assessments by evaluating change from baseline of Erythrocytes as per the study schedule
| x10^12 cells/L | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Cycle 1 | -0.002 ± 0.2425 | -0.038 ± 0.2194 | — |
| Cycle 2 | — | — | 0.032 ± 0.2091 |
| Cycle 3 | — | — | 0.063 ± 0.2619 |
| Cycle 4 | — | — | 0.041 ± 0.2716 |
Safety assessments by evaluating change from baseline of Erythrocytes MCV as per the study schedule
| fL | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Cycle 1 | -0.78 ± 2.615 | -0.79 ± 2.860 | — |
| Cycle 2 | — | — | -0.38 ± 3.070 |
| Cycle 3 | — | — | 0.53 ± 4.209 |
| Cycle 4 | — | — | 2.18 ± 3.875 |
Safety assessments by evaluating change from baseline of Erythrocyte MCHC, Hemoglobin as per the study schedule
| g/dL | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Week 4 of cycle 1 - Erythrocyte MCHC (g/dL) | 0.32 ± 0.954 | 0.33 ± 1.041 | — |
| Week 4 of cycle 1 - Hemoglobin (g/dL) | 0.02 ± 0.732 | -0.09 ± 0.740 | — |
| Week 4 of cycle 2 - Erythrocyte MCHC (g/dL) | — | — | 0.16 ± 1.070 |
| Week 4 of cycle 2 - Hemoglobin (g/dL) | — | — | 0.12 ± 0.638 |
| Week 4 of cycle 3 - Erythrocyte MCHC (g/dL) | — | — | -0.12 ± 1.366 |
| Week 4 of cycle 3 - Hemoglobin (g/dL) | — | — | -0.21 ± 0.821 |
| Week 4 of cycle 4 - Erythrocyte MCHC (g/dL) | — | — | -0.65 ± 1.306 |
| Week 4 of cycle 4 - Hemoglobin (g/dL) | — | — | -0.15 ± 0.921 |
Safety assessments by evaluating change from baseline of Lymphocytes/leukocytes, Monocytes/leukocytes, Neutrophils/leukocytes, Basophiles/leukocytes, Eosinophils/leukocytes as per the study schedule
| % of leukocytes | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Week 4 of cycle 1 - Basophiles/leukocytes (%) | 0.05 ± 0.669 | 0.14 ± 0.890 | — |
| Week 4 of cycle 1 - Eosinophils/leukocytes (%) | 0.14 ± 1.090 | 0.05 ± 1.292 | — |
| Week 4 of cycle 1 - Lymphocytes/leukocytes (%) | -0.26 ± 6.724 | -1.13 ± 5.468 | — |
| Week 4 of cycle 1 - Monocytes/leukocytes (%) | -0.40 ± 2.337 | -0.48 ± 2.350 | — |
| Week 4 of cycle 1 - Neutrophils/leukocytes (%) | 0.47 ± 7.610 | 1.41 ± 6.219 | — |
| Week 4 of cycle 2 - Basophiles/leukocytes (%) | — | — | -0.04 ± 0.837 |
| Week 4 of cycle 2 - Eosinophils/leukocytes (%) | — | — | 0.13 ± 1.554 |
| Week 4 of cycle 2 - Lymphocytes/leukocytes (%) | — | — | 0.80 ± 6.802 |
| Week 4 of cycle 2 - Monocytes/leukocytes (%) | — | — | -0.04 ± 1.559 |
| Week 4 of cycle 2 - Neutrophils/leukocytes (%) | — | — | -0.84 ± 7.660 |
| Week 4 of cycle 3 - Basophiles/leukocytes (%) | — | — | -0.25 ± 0.764 |
| Week 4 of cycle 3 - Eosinophils/leukocytes (%) | — | — | 0.06 ± 1.788 |
| Week 4 of cycle 3 - Lymphocytes/leukocytes (%) | — | — | 0.82 ± 7.814 |
| Week 4 of cycle 3 - Monocytes/leukocytes (%) | — | — | -0.16 ± 1.790 |
| Week 4 of cycle 3 - Neutrophils/leukocytes (%) | — | — | -0.47 ± 9.240 |
| Week 4 of cycle 4 - Basophiles/leukocytes (%) | — | — | -0.23 ± 0.663 |
| Week 4 of cycle 4 - Eosinophils/leukocytes (%) | — | — | -0.26 ± 1.191 |
| Week 4 of cycle 4 - Lymphocytes/leukocytes (%) | — | — | 1.68 ± 6.869 |
| Week 4 of cycle 4 - Monocytes/leukocytes (%) | — | — | 0.06 ± 2.434 |
| Week 4 of cycle 4 - Neutrophils/leukocytes (%) | — | — | -1.34 ± 7.460 |
Safety assessments by evaluating change from baseline of Systolic and Diastolic Blood Pressure as per the study schedule
| mmHg | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Week 4 of cycle 1 - Systolic Blood Pressure (mmHg) | -0.7 ± 11.13 | -0.2 ± 10.50 | — |
| Week 4 of cycle 1 - Diastolic Blood Pressure (mmHg) | -1.0 ± 7.54 | 1.3 ± 8.16 | — |
| Week 4 of cycle 2 - Systolic Blood Pressure (mmHg) | — | — | -0.9 ± 11.66 |
| Week 4 of cycle 2 - Diastolic Blood Pressure (mmHg) | — | — | 0.0 ± 7.79 |
| Week 4 of cycle 3 - Systolic Blood Pressure (mmHg) | — | — | -1.7 ± 12.06 |
| Week 4 of cycle 3 - Diastolic Blood Pressure (mmHg) | — | — | -0.4 ± 8.02 |
| Week 4 of cycle 4 - Systolic Blood Pressure (mmHg) | — | — | -1.8 ± 13.40 |
| Week 4 of cycle 4 - Diastolic Blood Pressure (mmHg) | — | — | -0.2 ± 7.38 |
Safety assessments by evaluating change from baseline of Pulse rate as per the study schedule
| bpm | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| Cycle 1 | -1.7 ± 10.83 | 0.1 ± 10.24 | — |
| Cycle 2 | — | — | 1.2 ± 9.11 |
| Cycle 3 | — | — | 2.2 ± 10.73 |
| Cycle 4 | — | — | 0.7 ± 10.73 |
Safety assessments by evaluating Electrocardiogram as per the study schedule
| Participants | Botulinum Toxin A - Normal Baseline Electrocardiogram Interpretation | Botulinum Toxin A - Abnormal Baseline Electrocardiogram Interpretation | Placebo - Normal Baseline Electrocardiogram Interpretation | Placebo - Abnormal Baseline Electrocardiogram Interpretation |
|---|---|---|---|---|
| Cycle 1 Week 4 - Electrocardiogram Interpretation — Normal | 223 | 5 | 71 | 3 |
| Cycle 1 Week 4 - Electrocardiogram Interpretation — Abnormal | 13 | 22 | 3 | 8 |
| Cycle 1 End of Cycle Visit - Electrocardiogram Interpretation — Normal | 198 | 6 | 69 | 3 |
| Cycle 1 End of Cycle Visit - Electrocardiogram Interpretation — Abnormal | 10 | 19 | 4 | 8 |
Collected over Up to 60 weeks post first treatment. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Botulinum Toxin A | 0/266 (0%) | 1/266 (0.4%) | 12/266 (4.5%) |
| Placebo | 0/89 (0%) | 1/89 (1.1%) | 6/89 (6.7%) |
| Botulinum Toxin A Open Label Extension Arm | 0/323 (0%) | 4/323 (1.2%) | 14/323 (4.3%) |
| Event | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| SyncopeNervous system disorders | 0/266 | 1/89 | 0/323 |
| Foot deformityMusculoskeletal and connective tissue disorders | 1/266 | 0/89 | 0/323 |
| Acute myocardial infarctionCardiac disorders | 0/266 | 0/89 | 1/323 |
| GoitreEndocrine disorders | 0/266 | 0/89 | 1/323 |
| CholecystitisHepatobiliary disorders | 0/266 | 0/89 | 1/323 |
| CholelithiasisHepatobiliary disorders | 0/266 | 0/89 | 1/323 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/266 | 0/89 | 1/323 |
| Event | Botulinum Toxin A | Placebo | Botulinum Toxin A Open Label Extension Arm |
|---|---|---|---|
| HeadacheNervous system disorders | 10/266 | 2/89 | 5/323 |
| NasopharyngitisInfections and infestations | 2/266 | 3/89 | 9/323 |
| Tooth fractureInjury, poisoning and procedural complications | 0/266 | 2/89 | 1/323 |
| Age, Categorical(Participants) | Botulinum Toxin A | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 233 | 81 | 314 |
| >=65 years | 33 | 8 | 41 |
| Age, Continuous(years) | Botulinum Toxin A | Placebo | Total |
|---|---|---|---|
| Mean | 52.2 ± 11.24 | 49.4 ± 12.36 | 51.5 ± 11.58 |
| Sex: Female, Male(Participants) | Botulinum Toxin A | Placebo | Total |
|---|---|---|---|
| Female | 248 | 80 | 328 |
| Male | 18 | 9 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Botulinum Toxin A | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 66 | 22 | 88 |
| Not Hispanic or Latino | 200 | 67 | 267 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Botulinum Toxin A | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 25 | 7 | 32 |
| White | 236 | 79 | 315 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Botulinum Toxin A | Placebo | Total |
|---|---|---|---|
| United States | 225 | 79 | 304 |
| Austria | 41 | 10 | 51 |
| Facial Wrinkle Scale at Maximum Frown by Investigator and Subject In-clinic Assessment(Participants) | Botulinum Toxin A | Placebo | Total |
|---|---|---|---|
| Investigator's In-clinic Assessment — No facial wrinkles | 0 | 0 | 0 |
| Investigator's In-clinic Assessment — Mild facial wrinkles | 0 | 0 | 0 |
| Investigator's In-clinic Assessment — Moderate facial wrinkles | 64 | 22 | 86 |
| Investigator's In-clinic Assessment — Severe facial wrinkles | 202 | 67 | 269 |
| Subject's In-clinic Assessment — No facial wrinkles | 0 | 0 | 0 |
| Subject's In-clinic Assessment — Mild facial wrinkles | 0 | 0 | 0 |
| Subject's In-clinic Assessment — Moderate facial wrinkles | 70 | 25 | 95 |
| Subject's In-clinic Assessment — Severe facial wrinkles | 196 | 64 | 260 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — This is not decided yet and will be changed accordingly when the decision has been made
Ran from Apr 2019 to primary completion in Dec 2019, 7 months.
Results were first posted in Jun 2025, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A